Cell therapy is one of the most exciting technologies for the treatment of diseases, yet despite the incredible progress, this modality still has many challenges MatchBio's mission is to unlock the full potential of cell therapy, solving the issue of low-sensitivity in chimeric antigen receptor (CAR-)based therapies. Through our range of bespoke synthetic receptors we can enhance the sensitivity of CAR-T therapies thereby reducing relapse, increasing efficacy and expanding the target landscape
| Website | https://www.matchbiotx.com |
| Employees | 9 (7 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Cell Therapy, Therapeutic Solutions, Cell Therapies, Immunotherapy, Treatment Solutions, Regenerative Medicine, Biotechnology, Advanced Therapies, Pharmaceutical, Drug Development, Innovative Therapies, Clinical Trials, Bioprocessing, Cell Engineering, Gene Therapy, Oncology, Precision Medicine, Rare Diseases, Biopharma, Life Sciences |
| Competitors | Novartis, Merck & Co., Inc., Pfizer, Bristol Myers Squibb, Genentech, Amgen, Regeneron, Gilead Sciences, Receptos, a wholly-owned subsidiary of Celgene, Lilly India +39 more (view full list) |
Looking for a particular MatchBio employee's phone or email?
Anton van der Merwe is the Founder of MatchBio.
7 people are employed at MatchBio.
MatchBio is based in Oxford, England.